Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health ...

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...